FDA Issues First of Four Draft Guidances on Patient-Focused Drug Development

Drug Industry Daily
A A
Sites and sponsors should have a lot of leeway in determining how to measure patient experiences during drug development but researchers should take care that they’re focusing on the right target population and whatever sampling methods they use are a fair representation of that target population, the FDA said in a new draft guidance.

To View This Article:

Login

Subscribe To Drug Industry Daily